Today at The DGTHT Hermedizin 2023
It was a pleasure to see Dr Rotering’s presentation today at the DGTHT Hermedizin 2023 conference. His presentation on the SteriPlas for the treatment of deep sternal wound infections shows just how effective our Cold Plasma medical device is for the treatment of these chronic and deep wounds infected with biofilm.
Not only has the SteriPlas has shown to significantly decrease hospital bed occupancy, but it has shown to reduce mortality rates and prevent the need for expensive treatments by allowing sternal wall stability. The SteriPlas can successfully kill all forms of bacteria, regardless of their resistance profile or if they are protected within biofilm.
SteriPlas heals wounds quickly
Did you catch the leading Serbian media newspaper, Večernje Novosti, last week? Our SteriPlas was featured in the article, “Cold plasma heals wounds quickly” composed by Dr Zorić.
Dr Zoric has been using our cold plasma medical device to treat hard-to-heal and stalled wounds infected with biofilm. These problematic wounds have responded very well with our SteriPlas treatment and patients have been healed that were otherwise stalled by conventional therapies.
If you are within Serbia and interested to learn more about our medical device, contact our medical distributor Borf Health Care on info@borf.biz for more information.
Dr H. Rotering presenting SteriPlas DSWI efficacy at Herzmidizin 2023 conference
Dr Heinrich Rotering will be presenting at the Herzmedizin 2023 conference on 14th February 2023. His presentation, “Tissue saving – Plasma based treatment concept for sternal infection including one year follow-up” will show the benefits of our SteriPlas cold plasma medical device for the treatment of deep sternal wound infections.
The benefit our cold plasma device has for these chronic wound infections is the ability to give a deep penetration treatment allowing plasma coverage over the wide infected area. As our medical device is the only microwave-powered, argon cold plasma device with a wide 12cm2 treatment size and is contact-free, the overall sessions are quickly completed. The mean wound healing for deep sternal wound infections is 16 days with the SteriPlas.
Contact us at info@adtecplasma.com to learn more about the SteriPlas.
New Wound Management of Driveline Infections with Cold Atmospheric Plasma
We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.
The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.
Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.
For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com
The ISHLT discusses the Cold Plasma Project
We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.
Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.
We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.
https://youtu.be/6-L0sgXLx9o
Welcoming Cardiothoracic Specialists at The SCTS
We're having a great time at the Society for Cardiothoracic Surgery in GB & Ireland conference, introducing the strong benefits of our Adtec SteriPlas cold plasma for deep sternal wound infections.
Please do pop by & see us at booth 18 to see our medical device in action.
The ISHLT Award Goes to Thomas Schlöglhofer!
Congratulations to Thomas Schlöglhofer and his team at the Medical University Hospital in Vienna for winning the ISHLT (International Society for Heart and Lung Transplantation) grant award, sponsored by Abbott and Medtronic.
This prestigious award given to Thomas is for his fantastic work using our Adtec SteriPlas medical device for the successful healing of LVAD Infections.
We look forward to continuing to support Thomas and his team and their presentation of the study at the ISHLT 2023 conference next year.
Next week welcomes the start of the exhibition season
Find us next week at the Society for Cardiothoracic Surgeons in Belfast from 8-10 May. We'll be at booth 18 ready to welcome you and introduce the benefits of #coldplasma in cardiothoracic #infection conditions.
From 10-13 May, we will also be exhibiting at the Malvern Diabetic Foot Conference looking forward to seeing regular faces from this prestigious conference.
We will have our Adtec SteriPlas medical device on our booths, ready to give you a live demonstration of how effective cold plasma is at killing bacteria protected within biofilm.
ToGCPiCPT
Congratulations to our Business Development Manager, Jeiram, for his published chapter in the “Textbook of Good Clinical Practice in Cold Plasma Therapy”. This prestigious book houses powerful material from esteemed authors in the cold plasma medicine field.
Jeiram’s chapter, “SteriPlas® and PlasmaTact®”, discusses the importance of Adtec Healthcare’s influence in the cold plasma medicine field from being the first company ever to conduct cold plasma clinical trials on wounds and to our modern day clinical efficacy in wounds, surgical site infections and medical dermatology skin conditions.
You can view this chapter here: https://doi.org/10.1007/978-3-030-87857-3_18
For more information about our cold plasma medical and non-medical devices, please contact us at info@adtecplasma.com
Our Cold Plasma Medical Device leads the way
Bacteria protected within biofilm are up to 1000x more resistant to antibiotics. This can complicate treatment options for wounds and surgical site infections but as it is an international form of therapy, it remains used throughout patient treatments despite it offering little to no help in healing problematic/stalled wounds and infections.
The cost burden associated to ongoing antibiotic therapy is significant as is the antimicrobial resistance rates that are ever growing. The World Health Organisation recognizes this and more hospitals are reaching out to alternative therapies to help curb the spending costs and antimicrobial resistance rates.
As the Adtec SteriPlas cold plasma has been shown to kill all forms of bacteria, regardless of their resistance profile or if they are Gram -ve or +ve or even if they are protected within biofilm, it has become widely adopted as an alternative to antibiotic therapy specifically in cases where patients are at a severe stage of infection such as those associated to diabetic foot ulcers and left ventricular assist device infections.
It has been praised as a life-saving medical device helping to heal infections that have been stalled for a very long time where conventional therapies have failed to act, reduce amputation and mortality rates.
This year we look forward to releasing a series of Health Economic publications documenting the cost effectiveness of our medical device against the use conventional therapies. We look forward to releasing this information to you in due time.
Until then, please reach out to us to learn more about why the interest in our medical device is growing daily. The data collection of our safety and efficacy shows why using an Adtec SteriPlas could completely change the way you treat patients.